

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(Use as many sheets as necessary)

Sheet 1 of 2


Complete If Known

Application Number	10/575,438
Filing Date	April 11, 2006
First Named Inventor	Christopher Wheeler
Art Unit	1642
Examiner Name	To be assigned
Attorney Docket Number	67789-570

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-6,632,459	10/14/2003	Graus et al.	
	2	US- 6,458,585	10/01/2002	Vachula et al.	
	3	US- 2003/0095955	05/22/2003	Noessner et al.	
	4	US- 2003/0185823	10/02/2003	Lum et al.	
	5	US- 2003/0190882	10/09/2003	Law et al.	
	6	US- 2003/0202863	10/30/2003	Crystal et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	7	WO 03/010301	2/06/2003	Immuno-Designed Molecules		
	8	WO 03/014335	2/20/2003	Bio-Clones (Proprietary) Limited		

Examiner Signature

Date Considered

10/4/07

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/575,438
			Filing Date	April 11, 2006
			First Named Inventor	Christopher Wheeler
			Art Unit	1642
			Examiner Name	To be assigned
			Attorney Docket Number	67789-570
(Use as many sheets as necessary)				
Sheet	2	of	2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	9	SHIN et al., Antitumor Effect of Intratumoral Administration Of Dendritic Cell Combination With Vincristine Chemotherapy In A Murine Fibrosarcoma Model, Histology and Histopathology, April 2003, pp. 435-447, 18:2.	
	10	YU et al., Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer, Clinical Cancer Research, January 2003, pp. 285-294, 9:1.	
	11	TANAKA et al., Intratumoral Injection of Dendritic Cells After Treatment of Anticancer Drugs Induces Tumor-Specific Antitumor Effect In Vivo, International Journal of Cancer, September 20, 2002, pp. 265-269, 101:3.	
	12	GHOSH et al., Dendritic Cell-Based Immunotherapy Combined With Antimony-Based Chemotherapy Cures Established Murine Visceral Leishmaniasis, The Journal of Immunology, June 1, 2003, pp. 5625-5629, 170:11.	
	13	INOUE et al., Dendritic Cell Cojected With Tumor Cells Treated With An Anticancer Drug To Induce Tumor Rejection, Surgery Today, April 4, 2003, pp. 269-276, 33:4.	
	14	REICHARDT et al., Idiotype Vaccination Of Multiple Myeloma Patients Using Monocyte-Derived Dendritic Cells, Haematologica, October 2003, pp. 1139-1149, 88:10.	
	15	CHUI et al., Dendritic Cell Vaccination Following High Dose Chemotherapy With Autologous Stem Cell Support For Breast Cancer: Long-Term Follow-Up, Proceedings of the American Society of Clinical Oncology, June 2003, 22 (ABSTRACT ONLY).	
	16	CASTRO et al., Current and Future Strategies For The Treatment Of Malignant Brain Tumors, Pharmacology & Therapeutics, April 2003, pp. 71-108, 98:1.	
	17	POLLACK et al., Exploitation of Immune Mechanisms in the Treatment of Central Nervous System Cancer, Seminars in Pediatric Neurology, June 2000, pp. 131-143, 7:2.	
	18	YU et al., Vaccination of Malignant Glioma Patients With Peptide-Pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-Cell Infiltration, Cancer Research, February 1, 2001, pp. 842-847, 61:3.	
	19	STEINMAN, R.M., Some Interfaces of Dendritic Cell Biology, Acta Pathologica, Microbiologica, et Immunologica Scandinavica, July 2003, pp. 675-697, 111:7-8.	

Examiner Signature		Date Considered	10/4/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.